{
    "hands_on_practices": [
        {
            "introduction": "The duration and intensity of a neurotransmitter's signal are critically controlled by how quickly it is cleared from the synaptic cleft. This exercise focuses on this fundamental process by modeling the action of the serotonin transporter (SERT), a key protein responsible for serotonin reuptake. By applying the classic Michaelis-Menten kinetics model, you will quantitatively explore how the rate of neurotransmitter removal changes with its concentration, revealing the crucial concept of transporter saturation and its impact on synaptic signaling .",
            "id": "4722968",
            "problem": "A neuron’s presynaptic membrane expresses the serotonin transporter (SERT; Serotonin Transporter), which clears serotonin, also known as $5$-hydroxytryptamine (5-HT), from the synaptic cleft. In a microdialysis experiment that monitors extracellular concentration as an effective compartment, the apparent maximum uptake capacity and the affinity of SERT are measured as $V_{\\max} = 2.5\\,\\mathrm{\\mu M\\cdot s^{-1}}$ and $K_m = 0.20\\,\\mathrm{\\mu M}$, respectively. At a time point immediately following vesicular release, the extracellular serotonin concentration is $[5\\text{-HT}] = 0.80\\,\\mathrm{\\mu M}$. Assuming transporter-mediated uptake follows the standard steady-state principles of Michaelis–Menten kinetics appropriate for a saturable transporter acting on its substrate in a well-mixed extracellular compartment, compute the reuptake flux $v$ at that moment. Then, explain qualitatively, based on first principles of saturable transport, how transporter saturation at high $[5\\text{-HT}]$ influences synaptic dwell time compared to the low-concentration regime. Round your numerical answer to three significant figures and express the reuptake flux in $\\mathrm{\\mu M\\cdot s^{-1}}$.",
            "solution": "The problem asks for the calculation of the reuptake flux of serotonin (5-HT) and a qualitative explanation of how transporter saturation affects its synaptic dwell time. The problem is valid as it is scientifically grounded in the principles of enzyme/transporter kinetics, is well-posed with all necessary information provided, and is expressed in objective, formal language.\n\nFirst, we address the quantitative part of the problem: computing the reuptake flux $v$ at a specific serotonin concentration. The problem states that the transporter-mediated uptake follows Michaelis–Menten kinetics. The Michaelis–Menten equation describes the rate of an enzyme-catalyzed reaction (or in this case, transporter-mediated flux), $v$, as a function of the substrate concentration, $[S]$. The equation is:\n$$v = \\frac{V_{\\max} [S]}{K_m + [S]}$$\nwhere:\n- $v$ is the reaction rate or flux.\n- $V_{\\max}$ is the maximum rate achieved by the system at saturating substrate concentration.\n- $K_m$ is the Michaelis constant, which is the substrate concentration at which the reaction rate is half of $V_{\\max}$.\n- $[S]$ is the concentration of the substrate.\n\nThe problem provides the following values:\n- Maximum uptake capacity, $V_{\\max} = 2.5\\,\\mathrm{\\mu M\\cdot s^{-1}}$.\n- Michaelis constant (affinity), $K_m = 0.20\\,\\mathrm{\\mu M}$.\n- Substrate concentration, $[S] = [5\\text{-HT}] = 0.80\\,\\mathrm{\\mu M}$.\n\nWe substitute these values into the Michaelis–Menten equation to calculate the reuptake flux $v$ at the given moment:\n$$v = \\frac{(2.5\\,\\mathrm{\\mu M\\cdot s^{-1}}) \\times (0.80\\,\\mathrm{\\mu M})}{0.20\\,\\mathrm{\\mu M} + 0.80\\,\\mathrm{\\mu M}}$$\nThe units of concentration ($\\mathrm{\\mu M}$) in the numerator and denominator need to be handled correctly.\n$$v = \\frac{2.5 \\times 0.80}{0.20 + 0.80} \\left( \\frac{\\mathrm{\\mu M\\cdot s^{-1}} \\cdot \\mathrm{\\mu M}}{\\mathrm{\\mu M}} \\right)$$\n$$v = \\frac{2.0}{1.00} \\,\\mathrm{\\mu M\\cdot s^{-1}}$$\n$$v = 2.0\\,\\mathrm{\\mu M\\cdot s^{-1}}$$\nThe problem requires the answer to be rounded to three significant figures. Thus, the reuptake flux is $v = 2.00\\,\\mathrm{\\mu M\\cdot s^{-1}}$.\n\nNext, we address the qualitative part of the problem: explaining how transporter saturation at high $[5\\text{-HT}]$ influences synaptic dwell time compared to the low-concentration regime.\n\nThe synaptic dwell time of a neurotransmitter is the duration it remains in the synaptic cleft before being cleared. This time is inversely related to the clearance rate (the reuptake flux $v$). The principles of saturable transport, as described by the Michaelis–Menten equation, dictate how this clearance rate behaves at different substrate concentrations.\n\n1.  **Low-Concentration Regime ($[5\\text{-HT}] \\ll K_m$)**:\n    When the serotonin concentration is much lower than the $K_m$, the term $[5\\text{-HT}]$ in the denominator ($K_m + [5\\text{-HT}]$) is negligible compared to $K_m$. The equation can be approximated as:\n    $$v \\approx \\frac{V_{\\max} [5\\text{-HT}]}{K_m} = \\left(\\frac{V_{\\max}}{K_m}\\right) [5\\text{-HT}]$$\n    In this regime, the reuptake flux $v$ is approximately directly proportional to the serotonin concentration $[5\\text{-HT}]$. This is characteristic of first-order kinetics. The clearance mechanism is highly efficient, and the system can rapidly respond to changes in neurotransmitter levels. The synaptic dwell time is short because the clearance rate scales linearly with the amount of substrate to be cleared.\n\n2.  **High-Concentration Regime ($[5\\text{-HT}] \\gg K_m$)**:\n    When the serotonin concentration is much higher than the $K_m$, a majority of the SERT binding sites are occupied. The transporter system is said to be saturated. In this case, the term $K_m$ in the denominator ($K_m + [5\\text{-HT}]$) becomes negligible compared to $[5\\text{-HT}]$. The equation can be approximated as:\n    $$v \\approx \\frac{V_{\\max} [5\\text{-HT}]}{[5\\text{-HT}]} = V_{\\max}$$\n    In this regime, the reuptake flux $v$ approaches its maximum possible value, $V_{\\max}$, and becomes largely independent of the serotonin concentration. This is characteristic of zero-order kinetics. The clearance system is operating at full capacity and cannot clear the neurotransmitter any faster, regardless of how much more is present.\n\n**Influence on Synaptic Dwell Time**:\nAt low concentrations, the clearance machinery is not overwhelmed, and the rate of removal keeps pace with the amount of neurotransmitter present, leading to a relatively short dwell time. However, at high concentrations that cause transporter saturation, the clearance rate hits a constant, maximum ceiling ($V_{\\max}$). If a large bolus of $5$-HT is released into the synapse (pushing $[5\\text{-HT}]$ into the saturation regime), the clearance rate cannot increase to match the high concentration. The removal process becomes a bottleneck. Consequently, the time required to clear the serotonin from the synaptic cleft is prolonged significantly. This increase in synaptic dwell time means that serotonin persists in the synapse for a longer duration, leading to enhanced and prolonged stimulation of postsynaptic (and presynaptic autoregulatory) receptors.\n\nIn summary, transporter saturation creates a non-linear relationship between neurotransmitter concentration and its clearance rate, causing the synaptic dwell time to increase disproportionately at high concentrations compared to the low-concentration, non-saturated regime.",
            "answer": "$$\n\\boxed{2.00}\n$$"
        },
        {
            "introduction": "Once a drug enters the brain, its therapeutic and adverse effects begin with binding to specific receptor proteins. This practice bridges the gap between molecular binding and clinical outcomes by first principles. You will derive the fundamental relationship between drug concentration and receptor occupancy, $\\theta$, then use this to model how increasing levels of receptor blockade can produce both desired antipsychotic efficacy and undesired side effects, ultimately integrating these into a single \"net clinical utility\" score . This exercise provides a powerful framework for understanding the dose-response relationship in psychopharmacology.",
            "id": "4722962",
            "problem": "In medical psychology, the antipsychotic efficacy and the risk of extrapyramidal side effects (EPS) are linked to the fraction of dopamine D2 receptors occupied by a drug. Consider a reversible binding equilibrium between a drug and the dopamine D2 receptor, modeled by $D + R \\rightleftharpoons DR$, where $D$ denotes free drug, $R$ denotes unbound receptor, and $DR$ denotes the drug–receptor complex. At equilibrium, the dissociation constant $K_{d}$ is defined by $K_{d} = \\frac{[D][R]}{[DR]}$. The receptor occupancy is defined as $\\theta = \\frac{[DR]}{[R] + [DR]}$. Assume the free extracellular brain concentration $[D]$ is effectively constant relative to the number of receptors.\n\nA novel antipsychotic has a measured dopamine D2 receptor dissociation constant $K_{d} = 12\\,\\mathrm{nM}$ and achieves a free extracellular brain concentration $[D] = 30\\,\\mathrm{nM}$ at steady state. Empirically, antipsychotic efficacy as a function of occupancy can be described by a Hill-type relationship $E(\\theta) = \\frac{\\theta^{h}}{\\theta^{h} + \\theta_{50}^{h}}$, with parameters $\\theta_{50} = 0.65$ and $h = 4$. The probability-like risk index for extrapyramidal side effects (EPS) is modeled by a logistic function $S(\\theta) = \\frac{1}{1 + \\exp\\!\\big(-k(\\theta - \\theta_{\\mathrm{EPS}})\\big)}$, with parameters $k = 50$ and $\\theta_{\\mathrm{EPS}} = 0.78$. Define a unitless net clinical utility index by $U = 0.8\\,E(\\theta) - 0.4\\,S(\\theta)$, representing a weighted balance of efficacy and side-effect liability.\n\nUsing only the law of mass action at equilibrium and the above model definitions, derive the receptor occupancy $\\theta$ from first principles, then compute $E(\\theta)$, $S(\\theta)$, and the net utility $U$. Express the final utility $U$ as a unitless number and round your final answer to four significant figures.",
            "solution": "The reversible binding equilibrium $D + R \\rightleftharpoons DR$ with dissociation constant $K_{d}$ obeys the law of mass action, which at equilibrium states\n$$\nK_{d} = \\frac{[D][R]}{[DR]}.\n$$\nThe receptor occupancy $\\theta$ is defined by the fraction of total receptors bound:\n$$\n\\theta = \\frac{[DR]}{[R] + [DR]}.\n$$\nWe solve for $\\theta$ in terms of $[D]$ and $K_{d}$. From the definition of $K_{d}$,\n$$\n[DR] = \\frac{[D][R]}{K_{d}}.\n$$\nThe total receptor concentration is $[R]_{\\mathrm{T}} = [R] + [DR]$. Substituting $[DR]$,\n$$\n[R]_{\\mathrm{T}} = [R] + \\frac{[D][R]}{K_{d}} = [R]\\left(1 + \\frac{[D]}{K_{d}}\\right).\n$$\nHence,\n$$\n\\theta = \\frac{[DR]}{[R]_{\\mathrm{T}}} = \\frac{\\frac{[D][R]}{K_{d}}}{[R]\\left(1 + \\frac{[D]}{K_{d}}\\right)} = \\frac{\\frac{[D]}{K_{d}}}{1 + \\frac{[D]}{K_{d}}} = \\frac{[D]}{[D] + K_{d}}.\n$$\nUsing the given values $[D] = 30\\,\\mathrm{nM}$ and $K_{d} = 12\\,\\mathrm{nM}$, the occupancy is\n$$\n\\theta = \\frac{30}{30 + 12} = \\frac{30}{42} = \\frac{5}{7} \\approx 0.7142857.\n$$\nNext, compute the efficacy via the Hill-type function with $\\theta_{50} = 0.65$ and $h = 4$:\n$$\nE(\\theta) = \\frac{\\theta^{4}}{\\theta^{4} + \\theta_{50}^{4}}.\n$$\nWe have $\\theta = \\frac{5}{7}$, so\n$$\n\\theta^{4} = \\left(\\frac{5}{7}\\right)^{4} = \\frac{625}{2401},\n$$\nand\n$$\n\\theta_{50}^{4} = (0.65)^{4} = \\left(\\frac{13}{20}\\right)^{4} = \\frac{28561}{160000}.\n$$\nTherefore,\n$$\nE(\\theta) = \\frac{\\frac{625}{2401}}{\\frac{625}{2401} + \\frac{28561}{160000}} = \\frac{625 \\cdot 160000}{625 \\cdot 160000 + 28561 \\cdot 2401} = \\frac{100000000}{168574961}.\n$$\nNumerically,\n$$\nE(\\theta) \\approx 0.59320794.\n$$\nNow compute the EPS risk via the logistic function with $k = 50$ and $\\theta_{\\mathrm{EPS}} = 0.78$:\n$$\nS(\\theta) = \\frac{1}{1 + \\exp\\!\\big(-k(\\theta - \\theta_{\\mathrm{EPS}})\\big)}.\n$$\nWe have\n$$\n\\theta - \\theta_{\\mathrm{EPS}} = \\frac{5}{7} - \\frac{39}{50} = \\frac{250 - 273}{350} = -\\frac{23}{350},\n$$\nhence\n$$\n-k(\\theta - \\theta_{\\mathrm{EPS}}) = -50\\left(-\\frac{23}{350}\\right) = \\frac{23}{7}.\n$$\nThus\n$$\nS(\\theta) = \\frac{1}{1 + \\exp\\!\\left(\\frac{23}{7}\\right)}.\n$$\nCompute $\\exp\\!\\left(\\frac{23}{7}\\right) = \\exp(3)\\exp\\!\\left(\\frac{2}{7}\\right) \\approx 20.085536923 \\times 1.330712059 \\approx 26.72806519,$ yielding\n$$\nS(\\theta) \\approx \\frac{1}{1 + 26.72806519} \\approx 0.0360609.\n$$\nFinally, the net clinical utility index is\n$$\nU = 0.8\\,E(\\theta) - 0.4\\,S(\\theta).\n$$\nSubstituting the numerical values,\n$$\nU \\approx 0.8 \\times 0.59320794 \\;-\\; 0.4 \\times 0.0360609 \\approx 0.47456635 \\;-\\; 0.01442436 \\approx 0.46014199.\n$$\nRounded to four significant figures as requested,\n$$\nU \\approx 0.4601.\n$$\nThe final utility is dimensionless.",
            "answer": "$$\\boxed{0.4601}$$"
        },
        {
            "introduction": "Few drugs are perfectly \"clean,\" meaning they often bind to multiple types of receptors, not just their intended therapeutic target. This exercise delves into the concept of polypharmacology, where a drug's overall clinical profile is determined by its full spectrum of receptor interactions. Using the binding affinities, or $K_i$ values, for a hypothetical antidepressant at its primary target and several \"off-targets,\" you will calculate a selectivity index and a weighted side-effect liability index, simulating the quantitative approach used in modern drug discovery to predict and understand a drug's potential for causing unwanted side effects .",
            "id": "4723028",
            "problem": "A novel antidepressant candidate, denoted as compound ADX-17, exhibits measurable binding to multiple neurotransmitter targets relevant to health and behavior. In medical psychology, side-effect liabilities of psychotropic drugs are often linked to off-target receptor interactions. Consider the following inhibition constants, defined as the inhibition constant ($K_i$, the concentration at which a competing ligand reduces binding by half under equilibrium competitive binding), measured in $\\mathrm{nM}$ for ADX-17 at key targets:\n\n- Serotonin transporter (SERT): $1\\,\\mathrm{nM}$\n- Histamine $\\mathrm{H1}$ receptor: $10\\,\\mathrm{nM}$\n- Muscarinic $\\mathrm{M1}$ receptor: $200\\,\\mathrm{nM}$\n- $\\alpha_1$ adrenergic receptor: $100\\,\\mathrm{nM}$\n- $5$-hydroxytryptamine $2\\mathrm{C}$ receptor ($5\\text{-HT}_{2\\mathrm{C}}$): $30\\,\\mathrm{nM}$\n- Dopamine $\\mathrm{D2}$ receptor: $1000\\,\\mathrm{nM}$\n\nAssume a steady-state free brain extracellular concentration of the drug of $5\\,\\mathrm{nM}$. Starting from the law of mass action for competitive ligand–receptor binding at equilibrium and standard receptor occupancy definitions, derive the receptor occupancy at each target as a function of the free drug concentration and $K_i$. Using these derived occupancies:\n\n1. Define a selectivity index $\\mathcal{S}$ for ADX-17 as the ratio of the serotonin transporter occupancy to the cumulative occupancy across the listed off-target receptors that are commonly implicated in side effects (histamine $\\mathrm{H1}$, muscarinic $\\mathrm{M1}$, $\\alpha_1$ adrenergic, $5\\text{-HT}_{2\\mathrm{C}}$, and dopamine $\\mathrm{D2}$). Compute $\\mathcal{S}$.\n\n2. Construct an overall side-effect liability index $\\mathcal{L}$ as a weighted sum of off-target occupancies with weights reflecting the relative contribution of each receptor to clinically observed side-effect domains in psychopharmacology, specified as follows: sedation ($\\mathrm{H1}$) weight $3.0$, anticholinergic ($\\mathrm{M1}$) weight $2.0$, orthostatic hypotension ($\\alpha_1$) weight $2.5$, weight gain ($5\\text{-HT}_{2\\mathrm{C}}$) weight $1.5$, and extrapyramidal symptoms ($\\mathrm{D2}$) weight $4.0$.\n\nCompute $\\mathcal{L}$ using the occupancies you derived. Round your final answer for $\\mathcal{L}$ to four significant figures, and express it as a unitless decimal. Your final reported answer must be only $\\mathcal{L}$.",
            "solution": "The problem will first be validated for scientific soundness, consistency, and completeness before a solution is attempted.\n\n### Step 1: Extract Givens\nThe data and definitions provided in the problem statement are as follows:\n- Drug candidate: ADX-$17$\n- Steady-state free brain extracellular concentration of drug, $[L]$: $5\\,\\mathrm{nM}$\n- Inhibition constants, $K_i$, for ADX-$17$ at various targets:\n    - Serotonin transporter (SERT): $K_{i, \\text{SERT}} = 1\\,\\mathrm{nM}$\n    - Histamine $\\mathrm{H1}$ receptor: $K_{i, \\text{H1}} = 10\\,\\mathrm{nM}$\n    - Muscarinic $\\mathrm{M1}$ receptor: $K_{i, \\text{M1}} = 200\\,\\mathrm{nM}$\n    - $\\alpha_1$ adrenergic receptor: $K_{i, \\alpha_1} = 100\\,\\mathrm{nM}$\n    - $5$-hydroxytryptamine $2\\mathrm{C}$ receptor ($5\\text{-HT}_{2\\mathrm{C}}$): $K_{i, 5\\text{-HT}_{2\\mathrm{C}}} = 30\\,\\mathrm{nM}$\n    - Dopamine $\\mathrm{D2}$ receptor: $K_{i, \\text{D2}} = 1000\\,\\mathrm{nM}$\n- Definition of selectivity index, $\\mathcal{S}$: The ratio of SERT occupancy to the cumulative occupancy of the five listed off-target receptors ($\\mathrm{H1}$, $\\mathrm{M1}$, $\\alpha_1$, $5\\text{-HT}_{2\\mathrm{C}}$, $\\mathrm{D2}$).\n- Definition of side-effect liability index, $\\mathcal{L}$: A weighted sum of off-target occupancies.\n- Weights for the liability index, $\\mathcal{L}$:\n    - $w_{\\text{H1}} = 3.0$ (sedation)\n    - $w_{\\text{M1}} = 2.0$ (anticholinergic)\n    - $w_{\\alpha_1} = 2.5$ (orthostatic hypotension)\n    - $w_{5\\text{-HT}_{2\\mathrm{C}}} = 1.5$ (weight gain)\n    - $w_{\\text{D2}} = 4.0$ (extrapyramidal symptoms)\n- Required output: The numerical value of $\\mathcal{L}$, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the established criteria:\n- **Scientifically Grounded**: The problem is based on fundamental principles of pharmacology and neurobiology, specifically receptor theory, ligand binding, and the relationship between receptor occupancy and physiological effects (both therapeutic and adverse). The concepts of $K_i$, receptor occupancy, selectivity, and weighted liability indices are standard tools in drug discovery and medical psychology. The given $K_i$ values are within a realistic range for a neuropsychiatric drug candidate. The problem is scientifically sound.\n- **Well-Posed**: The problem is clearly defined. It provides all necessary data (drug concentration, $K_i$ values, weights) and precise instructions for the calculations of receptor occupancy, $\\mathcal{S}$, and $\\mathcal{L}$. The requested output is a single, uniquely determinable numerical value.\n- **Objective**: The problem is stated in objective, technical language. The weights for the liability index are provided as given parameters for the model, not as absolute factual claims, which is an appropriate way to structure such a problem.\n- **Completeness and Consistency**: The problem is self-contained. There is no missing information required for the derivation and calculations. The given data are consistent and do not contain contradictions.\n- **Other Flaws**: The problem does not exhibit any other flaws such as being unrealistic, ill-posed, trivial, or unverifiable. The scenario is a plausible, albeit simplified, representation of an early-stage drug candidate evaluation.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. A full, reasoned solution will be provided.\n\nThe first step is to derive the equation for receptor occupancy ($O$) as a function of the free drug concentration, $[L]$, and the inhibition constant, $K_i$. The problem specifies to start from the law of mass action for competitive binding at equilibrium.\n\nLet $R$ represent the receptor, $L$ represent the drug (ligand), and $RL$ represent the drug-receptor complex. The binding equilibrium is:\n$$ R + L \\rightleftharpoons RL $$\nThe dissociation constant, $K_d$, is the ratio of concentrations at equilibrium:\n$$ K_d = \\frac{[R][L]}{[RL]} $$\nThe problem provides the inhibition constant, $K_i$, which, for a competitive ligand in this context, is equivalent to its dissociation constant, $K_d$. Therefore, we use $K_i$ in place of $K_d$.\n$$ K_i = \\frac{[R][L]}{[RL]} \\implies [R] = \\frac{K_i [RL]}{[L]} $$\nReceptor occupancy, $O$, is the fraction of total receptors that are bound by the ligand:\n$$ O = \\frac{[RL]}{[R]_{\\text{total}}} = \\frac{[RL]}{[R] + [RL]} $$\nSubstituting the expression for $[R]$ into the occupancy equation:\n$$ O = \\frac{[RL]}{\\frac{K_i [RL]}{[L]} + [RL]} $$\nFactoring out $[RL]$ from the denominator, which cancels with the numerator:\n$$ O = \\frac{1}{\\frac{K_i}{[L]} + 1} = \\frac{[L]}{[L] + K_i} $$\nThis is the standard Hill-Langmuir equation, which we will use for all subsequent calculations.\n\nGiven the steady-state drug concentration $[L] = 5\\,\\mathrm{nM}$, we can now calculate the occupancy for each target receptor. Let $O_X$ be the occupancy at target $X$.\n\nOccupancy at SERT:\n$$ O_{\\text{SERT}} = \\frac{[L]}{[L] + K_{i, \\text{SERT}}} = \\frac{5}{5 + 1} = \\frac{5}{6} $$\nOccupancy at off-targets:\n$$ O_{\\text{H1}} = \\frac{[L]}{[L] + K_{i, \\text{H1}}} = \\frac{5}{5 + 10} = \\frac{5}{15} = \\frac{1}{3} $$\n$$ O_{\\text{M1}} = \\frac{[L]}{[L] + K_{i, \\text{M1}}} = \\frac{5}{5 + 200} = \\frac{5}{205} = \\frac{1}{41} $$\n$$ O_{\\alpha_1} = \\frac{[L]}{[L] + K_{i, \\alpha_1}} = \\frac{5}{5 + 100} = \\frac{5}{105} = \\frac{1}{21} $$\n$$ O_{5\\text{-HT}_{2\\mathrm{C}}} = \\frac{[L]}{[L] + K_{i, 5\\text{-HT}_{2\\mathrm{C}}}} = \\frac{5}{5 + 30} = \\frac{5}{35} = \\frac{1}{7} $$\n$$ O_{\\text{D2}} = \\frac{[L]}{[L] + K_{i, \\text{D2}}} = \\frac{5}{5 + 1000} = \\frac{5}{1005} = \\frac{1}{201} $$\n\nNext, we compute the selectivity index $\\mathcal{S}$, defined as the ratio of SERT occupancy to the sum of off-target occupancies.\n$$ \\mathcal{S} = \\frac{O_{\\text{SERT}}}{\\sum O_{\\text{off-target}}} = \\frac{O_{\\text{SERT}}}{O_{\\text{H1}} + O_{\\text{M1}} + O_{\\alpha_1} + O_{5\\text{-HT}_{2\\mathrm{C}}} + O_{\\text{D2}}} $$\n$$ \\sum O_{\\text{off-target}} = \\frac{1}{3} + \\frac{1}{41} + \\frac{1}{21} + \\frac{1}{7} + \\frac{1}{201} \\approx 0.33333 + 0.02439 + 0.04762 + 0.14286 + 0.004975 \\approx 0.55318 $$\n$$ \\mathcal{S} \\approx \\frac{5/6}{0.55318} \\approx \\frac{0.83333}{0.55318} \\approx 1.5064 $$\n\nThe primary task is to compute the side-effect liability index $\\mathcal{L}$, defined as the weighted sum of off-target occupancies.\n$$ \\mathcal{L} = w_{\\text{H1}}O_{\\text{H1}} + w_{\\text{M1}}O_{\\text{M1}} + w_{\\alpha_1}O_{\\alpha_1} + w_{5\\text{-HT}_{2\\mathrm{C}}}O_{5\\text{-HT}_{2\\mathrm{C}}} + w_{\\text{D2}}O_{\\text{D2}} $$\nSubstituting the given weights and calculated occupancies:\n$$ \\mathcal{L} = (3.0)\\left(\\frac{1}{3}\\right) + (2.0)\\left(\\frac{1}{41}\\right) + (2.5)\\left(\\frac{1}{21}\\right) + (1.5)\\left(\\frac{1}{7}\\right) + (4.0)\\left(\\frac{1}{201}\\right) $$\nWe evaluate each term:\n$$ \\mathcal{L} = 1 + \\frac{2}{41} + \\frac{2.5}{21} + \\frac{1.5}{7} + \\frac{4}{201} $$\nTo work with fractions, we express the decimal weights as fractions: $2.5 = \\frac{5}{2}$ and $1.5 = \\frac{3}{2}$.\n$$ \\mathcal{L} = 1 + \\frac{2}{41} + \\frac{5/2}{21} + \\frac{3/2}{7} + \\frac{4}{201} $$\n$$ \\mathcal{L} = 1 + \\frac{2}{41} + \\frac{5}{42} + \\frac{3}{14} + \\frac{4}{201} $$\nNow, we calculate the numerical value of this sum:\n$$ \\mathcal{L} = 1.0 + \\frac{2}{41} + \\frac{5}{42} + \\frac{3}{14} + \\frac{4}{201} $$\n$$ \\mathcal{L} \\approx 1.0 + 0.0487804878... + 0.119047619... + 0.214285714... + 0.0199004975... $$\n$$ \\mathcal{L} \\approx 1.4020143183... $$\nThe problem requires the final answer for $\\mathcal{L}$ to be rounded to four significant figures.\nThe first four significant figures are $1$, $4$, $0$, and $2$. The fifth significant figure is $0$, so we round down.\n$$ \\mathcal{L} \\approx 1.402 $$\nThis is the final numerical answer.",
            "answer": "$$\n\\boxed{1.402}\n$$"
        }
    ]
}